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PI3Ks (phosphoinositide 3-kinases) are signalling molecules and
drugtargetswithimportantbiologicalfunctions,yettheregulation
of PI3K gene expression is poorly understood. Key PI3Ks are
the class IA PI3Ks that consist of a catalytic subunit (p110α,
p110β and p110δ) in complex with a p85 regulatory subunit.
Whereas p110α and p110β are ubiquitously expressed, high
levels of p110δ are mainly found in white blood cells, with most
non-leucocytes expressing low levels of p110δ. In the present
paper we report that TNFα (tumour necrosis factor α) stimulation
induces p110δ expression in human ECs (endothelial cells) and
synovial ﬁbroblasts, but not in leucocytes, through transcription
start sites located in a novel promoter region in the p110δ gene
(PIK3CD). This promoter is used in all cell types, including solid
tumour cell lines that express p110δ, and is activated by TNFα
in ECs and synovial ﬁbroblasts. We further present a detailed
biochemical and bioinformatic characterization of p110δ gene
regulation, demonstrating that PIK3CD has distinct promoters,
some of which can be dynamically activated by pro-inﬂammatory
mediators. This is the ﬁrst molecular identiﬁcation of a PI3K
promoter under the control of acute extracellular stimulation.
Key words: bioinformatics, cytokine, inﬂammation, promoter,
PIK3CD, tumour necrosis factor α (TNFα).
INTRODUCTION
PI3Ks (phosphoinositide 3-kinases) phosphorylate inositol lipids
in cellular membranes in response to a variety of stimuli. The
involvement of PI3Ks in immunity, inﬂammation and cancer has
made these enzymes important new targets for drug development
[1–3]. This also applies to p110δ, a PI3K isoform mainly
expressed in leucocytes [4,5], and Phase I/II trials with p110δ
inhibitorsarecurrentlyinprogressforallergyandhaematological
malignancies [6,7].
Previous studies have started to uncover the molecular
mechanism of the selective enrichment of p110δ in the
haematopoietic lineage. p110δ expression is mainly regulated at
the transcriptional level with the protein being produced from
transcripts with different 5
 -UTRs (untranslated regions) as a
consequence of the presence of multiple TSSs (transcription start
sites) in the p110δ gene (PIK3CD in humans and Pik3cd in mice)
[8]. The 5
 -UTR of most p110δ transcript types contains two
untranslated exons, referred to as exons −1a n d−2. Of the
latter, two distinct species have been found in humans (−2a and
−2b) and four in mice (−2a, −2b, −2c and −2d), with only
exon −1 and a region of exon−2a being conserved between
humans and mice [8]. In both human and mouse leucocytes, the
p110δ transcript containing exons −2a and −1 is the most
abundant, in line with the presence of a conserved region of
predicted binding sites for leucocyte-speciﬁc TFs (transcription
factors) intheproximalpromoterregionoftheTSSofexon −2a.
Upon transient transfection this region of the murine genome has
a higher promoter activity in leucocytes than in non–leucocytes,
andthereforeprobablycontributestothehighexpressionofp110δ
in haematopoietic cells [8].
In addition to leucocytes, some non-leucocytes such as
melanocytes,breastcellsandtheirtransformedequivalents[8,10],
neurons [11], ECs (endothelial cells) [12] and lung ﬁbroblasts
[13] also express p110δ, albeit at lower levels than in leucocytes.
It is unclear how the expression of p110δ is controlled in these
cells.Inaddition,p110δ expressioncanbeincreasedinsomenon-
leucocytessuchasinrataortictissueuponlong-termtreatment(2–
4 weeks) with hypertension-inducing agents [DOCA (deoxycor-
ticosterone acetate) or N
ω-nitro-L-arginine] [14], in rat and mouse
cardiac ﬁbroblasts upon a more acute stimulation (30–60 min)
with aldosterone [15] and in the aortas of diabetic mice [16].
Thesestudies,however,didnotaddresstheregulatorymechanism
underlying the observed increase in p110δ levels.
We report in the present paper that TNFα (tumour necrosis
factor α) stimulation induces the expression of p110δ in human
ECs and synovial ﬁbroblasts. We describe a novel and inducible
human PIK3CD promoter region that gives rise to p110δ
transcripts with previously unidentiﬁed 5
 -UTRs. We further
analyse and discuss these observations in the broader context
of the distinct PIK3CD promoters that direct p110δ expression in
different cell types.
EXPERIMENTAL
Antibodies and reagents
Antibodies were as follows: anti-p110α (C73F8) (catalogue
number 4249), anti-p110β (C33D4) (catalogue number 3011),
anti-[p38 MAPK (mitogen-activated protein kinase) (phospho-
Thr
180/Tyr
182)] (3D7) (catalogue number 9215) and anti-[NF-κB
Abbreviations used: ActD, actinomycin D; ChIP, chromatin immunoprecipitation; ChIP-seq, ChIP sequencing; DMEM, Dulbecco’s modiﬁed Eagle’s
medium; EC, endothelial cell; ENCODE, Encyclopedia of DNA Elements; EST, expressed sequence tag; FBS, fetal bovine serum; H3K27Ac, histone 3
Lys27 acetylation;H3K4Me1,monomethylationofhistone3Lys4;H3K4Me3,trimethylationofhistone3Lys4;HUVEC,humanumbilicalveinEC;IκB,inhibitory
κB; IKK, IκB kinase; IL, interleukin; NF-κB, nuclear factor κB; PI3K, phosphoinositide 3-kinase; qPCR, quantitative PCR; 5 RACE, rapid ampliﬁcation of 5 
cDNA ends; SV40, simian virus 40; TF, transcription factor; TNFα, tumour necrosis factor α; TSS, transcription start site; UCSC, University of California
Santa Cruz; UTR, untranslated region.
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(nuclear factor κB) p65 (phospho-Ser
536)] (93H1) (catalogue
number 3033) (Cell Signaling Technology); anti-p110δ (H-219)
(catalogue number sc-7176) and anti-IκB (inhibitory κB)-α
(catalogue number sc-371) (Santa Cruz Biotechnology); anti-
p85 (catalogue number 06-195; Upstate Biotechnology);
anti-α-tubulin (B-5-1-2) and anti-vinculin (clone hVIN-1)
(Sigma). Carrier-free recombinant human TNFα was from
R&D Systems and recombinant human IL (interleukin)-1β was
from Peprotech. ActD (actinomycin D) was from Sigma and IKK
(IκB kinase) inhibitor VII from Calbiochem.
Cell culture and cell stimulation
HUVECs (human umbilical vein ECs) were purchased from
Lonza and cultured in EGM-2 medium (Lonza). HUVECs were
grown on plastic coated with human ﬁbronectin (10 μg/ml;
Sigma) and used for experiments between passages 3 and 5.
Culture media for cell lines were as follows: EA.hy926 (provided
by Professor Anne Ridley, King’s College London, University
of London, London, U.K.), U-87 MG and MDA-MB-468 cells,
DMEM (Dulbecco’s modiﬁed Eagle’s medium) supplemented
with 10% FBS (fetal bovine serum); SK-OV-3 cells, McCoy’s
5A medium supplemented with 10% FBS; and THP-1, Jurkat
and MCF-7 cells, RPMI 1640 supplemented with 10% FBS.
Synovial tissues were obtained from patients undergoing total
knee/hip replacement after informed consent (local research
ethics committee reference number 05/Q0703/198) and used
for isolation of synovial ﬁbroblasts as described previously
[17]. Synovial ﬁbroblasts were cultured in DMEM/Ham’s F12
supplemented with 10% FBS and 10 mM Hepes and used for
experiments between passages 6 and 9 when the culture is devoid
of contaminating lymphocytes and macrophages [18]. All cells
were maintained at 37◦Ca n d5% CO2. All cytokine stimulations
were performed in complete culture medium, deﬁned as medium
containing FBS and antibiotics.
Western blotting
Cells were collected and lysed in lysis buffer [50 mM Tris/HCl
(pH 7.4), 150 mM NaCl, 1 mM EDTA and 1% (v/v) Triton X-
100] supplemented with protease inhibitors. Equal amounts of
protein were separated by SDS/PAGE (8% gels), immunoblotted
with primary antibodies and HRP (horseradish peroxidase)-
conjugated species-speciﬁc secondary antibodies and exposed
to X-ray ﬁlm. A Bio-Rad Laboratories GS-800 calibrated
densitometer was used to quantify Western blot signals.
qPCR (quantitative PCR)
Total RNA was isolated using RNeasy Mini Kit (Qiagen).
Equal amounts of RNA were transcribed to cDNA with
SuperScript II reverse transcriptase using random primers
(Invitrogen). TaqMan Gene Expression Assays were from
Applied Biosystems: Hs00180679 (p110α), Hs00178872_m1
(p110β), Hs00192399_m1 (p110δ), Hs00933163 (p85α),
Hs00178181_m1 (p85β), Hs99999034_m1 (IL-8), eukaryotic
18S rRNA (4310893E) and β-actin (4326315E). Custom-
designed assays were used for speciﬁc human p110δ transcripts
(sequences provided in Supplementary Table S1 at http://www.
BiochemJ.org/bj/443/bj4430857add.htm). Samples were meas-
ured in triplicate using TaqMan Universal PCR Mastermix
(4440044). The   CT method [19] was used for relative
quantiﬁcation. For absolute quantiﬁcation of transcript copy
numbers, a standard curve of linearized plasmid (molecules/μl)
was generated for each amplicon. A dilution series of cDNA
preparedfromTHP-1cellswasusedasstandardcurveforβ-actin.
5 RACE (rapid ampliﬁcation of 5  cDNA ends)
5
 RACE was performed on 10 μg of total cellular RNA with
the FirstChoice RLM-RACE kit (Ambion). Nested PCR products
(primer sequenceslisted in SupplementaryTableS1)wereligated
into pGEM-T Easy (Promega) and transformed into Escherichia
coli OneShot TOP10 competent cells (Invitrogen). Clones of
transformed bacteria were isolated and puriﬁed DNA analysed
by sequencing.
Cloning of pGL3 reporter constructs
pGL3-Basic (E1751), pGL3-SV40 (E1761), pRL-SV40 (Renilla;
E2231) were from Promega. Regions surrounding human
PIK3CD exons −2a and −2e (−139 to +92 and −385
to +197 relative to the start sites of exons −2a and −2e
respectively) were PCR-ampliﬁed and inserted into pGL3-
Basic using the MluI/BglII sites (primer sequences shown in
Supplementary Table S1). The sequence surrounding exon −2c
[−640 to +310 relative to start site of exon −2c according
to EST (expressed sequence tag) DB216922] with ﬂanking 5
 
MluI and 3
  BglII sites was synthesized by OriGene Technologies
and subcloned into pGL3-Basic using the MluI/BglII sites. The
QuikChangeSite-DirectedMutagenesisKit(Stratagene)wasused
to mutate the NF-κB site in pGL3-exon-2e (primer sequences
shown in Supplementary Table S1).
Transfection and reporter gene assays
Cells in 12-well plates were co-transfected in triplicate with
0.5 μg/well pGL3-luc plasmid and 0.25 μg/well pRL-SV40
using FuGENE. Cells received complete medium with TNFα
(10 ng/ml) or complete medium only (unstimulated control) 24 h
after transfection. Lysates were prepared 48 h after transfection
using the Dual-Luciferase Reporter Assay System (Promega) and
luciferase activity was analysed using a Wallac 1420 VICTOR
3
Multilabel Counter (PerkinElmer). Renilla luciferase activity was
used to normalize transfection efﬁciency. Promoter activity
was expressed as the percentage of the activity of the pGL3-
SV40 reporter. The promoter of the Vav gene [20] cloned into
the pGL2 luciferase reporter was used as control for leucocyte-
speciﬁc promoter activity [8].
Bioinformatic analysis of the human PIK3CD locus
Thesequencesofthep110δ exons −2c, −2dand −2eidentiﬁed
in 5
 RACE clones were queried against the EST database
using NCBI Blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The
Ensembl genome database (GRCh37 assembly, release 64)
was used to inspect annotated human p110δ transcripts. The
TFSEARCHprogrammev.1.3wasusedtopredictNF-κB-binding
sites using the vertebrate matrix with a threshold of 90 points
(http://www.cbrc.jp/research/db/TFSEARCH.html).
The PIK3CD locus (chr1:9,605,000-9,715,721) was analysed
in the Human March 2006 (NCBI36/hg18) Assembly of the
UCSC (University of California Santa Cruz) genome browser
(http://genome.ucsc.edu/) for the presence of transcriptional
regulatory elements using the genome-wide data generated by
the ENCODE (Encyclopedia of DNA Elements) consortium [21].
Sequence conservation is depicted in the form of a multiple
sequence alignment of the corresponding genomic sequences
of chimp, mouse, rat, cow and dog generated using the MultiZ
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track. The DNase Clusters track shows DNase I-hypersensitivity
sites known to be associated with gene-regulatory regions.
The Txn Factor ChIP track shows TF binding to DNA as
assessed by ChIP-seq [ChIP (chromatin immunoprecipitation)-
sequencing]. The data for the DNase Clusters and Txn Factor
ChIP tracks was from Gm12878 and K562 cells. The
CpG islands track shows predictions of CpG islands using
the following criteria: GC content>50%; >200 bp length;
observed>expected CG dinucleotides ratio0.6. The Eponine
track shows TSS predictions and the FirstEF track predictions
of 5
 -terminal exons and associated promoters. The track
containing ChIP-seq data of promoter and enhancer-associated
histone modiﬁcations [H3K4Me1 (monomethylation of histone
3L y s
4) and H3K4Me3 (trimethylation of histone 3 Lys
4)
and H3K27Ac (histone 3 Lys
27 acetylation)] was divided into
leucocytes [Gm12878 (transformed human B-lymphocyte) and
K562(chronicmyelogenousleukaemia)]andnon-leucocytes[H1
ES (undifferentiated embryonic stem cells), HMECs (human
mammary epithelial cells), HSMMs (normal human skeletal
muscle myoblasts), HUVECs, NHEKs (normal human epidermal
keratinocytes), NHLFs (normal human lung ﬁbroblasts) and
HepG2 cells (human hepatocellular carcinoma cells; not included
in the H3K4Me1 track)]. The data tracks were exported from the
UCSC genome browser and compiled using Adobe Illustrator.
Bioinformatic analysis of the mouse Pik3cd locus
The Ensembl database (NCBIM37 assembly, release 64) was
inspected for annotated mouse p110δ transcripts. The mouse
Pik3cd locus was inspected in the UCSC genome browser
(NCBI37/mm9 assembly). ChIP-seq data from the histone
modiﬁcationtrack[ENCODE/LICR(LudwigInstituteforCancer
Research)] for the promoter-associated H3K4Me3 modiﬁcation
in different tissue and cell types are shown in Figure 4, and
Supplementary Figures S3 and S4 at http://www.BiochemJ.org/
bj/443/bj4430857add.htm.Thedatatrackswereexportedfromthe
UCSC genome browser and compiled using Adobe Illustrator.
RESULTS
TNFα stimulation increases p110δ expression in human ECs and
synoviocytes
Given the involvement of p110δ in immune cell signalling
and inﬂammation [22], we explored whether p110δ expression
could be modulated by inﬂammatory cytokines such as TNFα
and IL-1β, particularly in cell types that normally express low
levels of this protein. The endothelium plays an important
role in inﬂammation and we therefore analysed whether these
inﬂammatory mediators could induce PIK3CD gene expression
in ECs. Indeed, TNFα stimulation of HUVECs and the human
endothelium-derived cell line EA.hy926 (a cell hybrid of
HUVECs and A549 human pulmonary adenocarcinoma cells
[23]) increased the levels of p110δ protein (Figure 1A) and
mRNA (Figure 1B). A similar enhancement in the expression
of p110δ protein (Figure 1C) and mRNA (Figure 1D) upon
TNFα stimulationwasalsodetectedinhumansynovialﬁbroblasts
isolated from patients with rheumatoid arthritis. In contrast
with the consistent and highly reproducible increase in p110δ
expression upon TNFα stimulation, only slight increases in the
expression of p110α and p110β were noted in some, but not
all, experiments. However,p110δ expression inTNFα-stimulated
ECs remained lower compared with the basal levels of this PI3K
isoform in the leucocyte cell line THP-1 (Supplementary Figure
S1 at http://www.BiochemJ.org/bj/443/bj4430857add.htm).
The expression of PIK3CD mRNA was also increased
upon IL-1β stimulation of HUVECs and synovial ﬁbroblasts
(Supplementary Figure S2 at http://www.BiochemJ.org/bj/443/
bj4430857add.htm),butnotEA.hy926(resultsnotshown),inline
with the notion that EA.hy926 cells are not responsive to IL-1β
[24,25]. To determine whether TNFα-induced p110δ expression
was a common phenomenon or limited to ECs and synovial
ﬁbroblasts, we extended our analysis to include different human
and murine cell types. To our surprise, TNFα stimulation had
only a minor or no effect on p110δ mRNA or protein levels in the
other cell types that we tested (Supplementary Table S2 at http://
www.BiochemJ.org/bj/443/bj4430857add.htm). Interestingly,
p110δ expression was not induced in murine ECs (primary lung
or cardiac ECs) upon stimulation with TNFα (results not shown).
TNFα regulates cellular mRNA levels by inducing de
novo transcription and/or by stabilizing existing transcripts.
To determine whether TNFα increased cellular p110δ levels
throughatranscriptionalmechanism,wepre-treated ECswiththe
transcriptional inhibitor ActD prior to stimulation with TNFα.
The only way in which TNFα stimulation could increase
PIK3CD mRNA levels in ActD-treated cells would be through
enhancing the stability of existing p110δ transcripts. However,
TNFα stimulation did not signiﬁcantly alter the stability of
p110δ transcripts in ActD-treated HUVECs or EA.hy926 cells
(Figure 1E), demonstrating that TNFα induces p110δ expression
by stimulating the transcription of PIK3CD.
TNFα stimulation induces expression of PIK3CD mRNA transcripts
that contain novel 5  untranslated exons
Baseline p110δ transcripts in ECs contained exon −1, without
−2 exons (results not shown). We next used 5
 RACE to
identify the structure of the 5
 -UTR of PIK3CD mRNA
transcripts induced by TNFα stimulation of HUVECs and
EA.hy926 cells (Figure 2A). A single PCR product was
present in unstimulated cells, whereas TNFα stimulation led
to the appearance of additional PCR products (Figures 2B and
2C). Cloning and sequencing of these PCR products revealed
previously unidentiﬁed PIK3CD 5
 -UTRs containing three new
untranslated exons, located in close proximity to each other
in the human genome, approximately 3 kb upstream of exon
−1 (Figures 2D and 3A). In line with the nomenclature of
currently known ﬁrst exons of human PIK3CD (exon −2a and
−2b), the new exons were named exons −2c, −2d and −2e
(Figure 2D). All of the −2 exons identiﬁed contain a canonical
splicedonorsite,withexon −2dalsocontainingaspliceacceptor
site (Figure 2D and Table 1). Accordingly, each −2 exon was
spliced to the 5
 -end of exon −1t h a ti sc o m m o nt oa l lPIK3CD
transcripts (shown schematically in Figure 2D). In addition, a
further 5
 RACE product with exon −2d spliced between exons
−2e and −1 was found in TNFα-stimulated EA.hy926 cells
(Figures 2D and 3A).
Mouse Pik3cd transcripts with 5
  untranslated exons with a
genomic location corresponding to that of human exons −2c,
−2d and −2e were present in the Ensembl database (Figure 3B,
transcripts E, G, H and I), with the ﬁrst exon of transcripts E
and G (Figure 3B, boxed) being homologous with human exon
−2c(resultsnotshown).Itisimportanttonotethatthepreviously
adoptednomenclatureforthemurinep110δ exons −2cand −2d
[8] (Figure 3B) does not correlate with the nomenclature and
genomic location of the human p110δ exons −2c and −2d.
Figure 3 shows a graphical representation of the different human
and mouse PIK3CD/Pik3cd transcripts identiﬁed to date (full
details of the 5
  untranslated exons in human PIK3CD are shown
in Table 1).
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Figure 1 TNFα stimulation induces p110δ expression in human ECs
(A) PI3K isoform expression in HUVECs (upper panels) and EA.hy926 cells (lower panels) stimulated with TNFα (20ng/ml for HUVECs and 10 ng/ml in EA.hy926 cells) for the indicated times. A
representative immunoblot of three independent experiments is shown. Fold change in p110 isoform expression relative to unstimulated cells upon 18h stimulation with TNFα (right-hand panels)
as quantiﬁed by densitometry. Results are means+ −S.D. for three independent experiments. (B) PI3K mRNA expression in HUVECs (upper panels) and EA.hy926 cells (lower panels) stimulated
with TNFα (10ng/ml) for the indicated times and analysed by qPCR. Transcript expression was normalized to 18S rRNA and shown as fold increase over unstimulated levels for each transcript.
Results are means+ −S.E.M. for three independent experiments. (C) PI3K isoform expression in synovial ﬁbroblasts stimulated with TNFα (10ng/ml) for 18h. (D) PIK3CD mRNA expression in
synovial ﬁbroblasts stimulated with TNFα (10ng/ml) for 18h and analysed by qPCR. Transcript expression was normalized to 18S rRNA and shown as fold increase over unstimulated levels for
each transcript. Results are means+ −S.E.M. for three independent experiments. (E) HUVECs (left-hand panel) and EA.hy926 cells (right-hand panel) were pre-treated with ActD (4μg/μl) for 1 h
and either exposed to 10ng/ml TNFα or left unstimulated for the indicated times. p110δ mRNA levels were analysed by qPCR and normalized to 18S rRNA. The results are presented relative to the
p110δ levels after 1h of ActD treatment (t =0). Results are means+ −S.E.M. for three independent experiments. n.s., not signiﬁcant.
Bioinformatic analysis of the PIK3CD/Pik3cd locus supports the
existence of a novel PIK3CD/Pik3cd promoter, active in both
leucocytes and non-leucocytes
We previously showed that a conserved genomic region of mouse
Pik3cd exon −2a has higher promoter activity in leucocytes than
in non-leucocytes, which is probably due to a cluster of binding
sites for leucocyte-speciﬁc TFs in this region [8]. The promoters
associated with the other known mouse TSSs and with the human
PIK3CD TSSs have not been identiﬁed to date.
To gain more insight into the regulation of p110δ expression,
weanalysedthenatureofpotentialregulatoryelementsassociated
with the different TSSs in both the human and mouse
PIK3CD/Pik3cd genes. To this end, we used genome-wide data
on regulatory elements compiled by the ENCODE project [21],
available in the UCSC genome browser. Figure 4 shows the
human PIK3CD locus in the UCSC genome browser and a
selection of regulatory elements. The 5
 -UTR in the PIK3CD
reference mRNA transcript (RefSeq) is formed of exons −2a
and −1. We extended the region of analysis approximately 25 kb
upstream of exon −2a in order to include the TSS of exon
−2b. A multiple species alignment showed that in addition to
the coding region of PIK3CD, selected areas in the upstream
genomic region showed conservation across mammals (Figure 4,
sequence conservation panel). Interestingly, we found that
cis-a n dtrans-acting regulatory elements commonly associated
with transcriptional regulation, including chromatin accessibility
(DNase clusters), occupied TF-binding sites (Txn Factor ChIP)
and Eponine and FirstEF promoter predictions, clustered in three
regions (Figure 4, regions 1–3). As expected, two of these regions
were associated with the previously identiﬁed exons −2b and
−2a (Figure 4, regions 1 and 2). Interestingly, the location of the
third cluster of regulatory elements (Figure 4, region 3) coincided
withthatofthenewlyidentiﬁedexons −2c, −2dand −2e.This
genomic region upstream of exon −1 was not known previously
to contain a promoter.
Speciﬁc covalent modiﬁcations of histones have been shown to
be associated with gene regulatory regions such as promoters and
enhancers [21,26]. The ENCODE data on histone modiﬁcations
(H3K4Me1, H3K27Ac and H3K4Me3) have been compiled from
different human cell types (Figure 4 and Supplementary Figure
S3 at http://www.BiochemJ.org/bj/443/bj4430857add.htm, rep-
resented by a different colours). As the expression of p110δ is
highly polarized depending on the cell type, we analysed histone
c   The Authors Journal compilation c   2012 Biochemical Society © 2012 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Inducible expression of p110δ PI3K 861
Table 1 Summary of 5  untranslated exons in human PIK3CD
Details of all 5  untranslated exons of human PIK3CD identiﬁed to date. Exonic sequences are shown in upper case and intronic in lower case with splice donor and acceptor sequences indicated
in bold. A BLAST search for human ESTs found two containing exon −2c (GenBank® accession numbers DB216922 and DA318970 isolated from trachea and hippocampus respectively) with the
TSS of exon −2c in DB216922 located 53bp upstream of the 5 -end of the exon −2c present in the 5 RACE. One EST with a partial exon −2d sequence 2d was found (GenBank® accession
number AA188126; transcript I in Figure 3A). No signiﬁcant hits were obtained when the sequence of exon −2e was queried against the EST database.
Exon bp TSS distance from ATG (kb) Splice acceptor 5 -end of exon 3 -end of exon Splice donor
−2e 41 23 ggctccgcc CTCTCCCGGG GTGCGGGCGG gtgagtgcc
−2d 183 22 tcttctcag GCACGAGGAA TGTGGCAAAG gtttgtctt
−2c (5 RACE) 124 21 ccctccggc CCCCGCCGGC GCGACACCCG gtacggagc
−2c (EST) 177 21 ggccgcgcc CCTCCGCCGA GCGACACCCG gtacggagc
−2b 251 81 cgggggtca GAGGCGCCCA ACTCTGACAG gtgagtcta
−2a 59 58 gcgcccagc GCAGTCGCTC CGCCGGGACG gtaagcgat
−1 105 19 ccccaacag ATAAGGAGTC TTCCAGAGAG gtaggttgg
Figure 2 Novel TNFα-inducible PIK3CD TSSs uncovered by 5 RACE in human ECs
(A) Schematic representation of the 5 RACE strategy used to analyse the PIK3CD 5 -UTR in human ECs. The 5 RACE adapter is shown in grey, the 5 -UTR of the human PIK3CD mRNA transcript is
shown in white and the protein-coding exons are shown in black. The approximate binding sites of the outer and inner primers used in the nested PCR are depicted with arrows. (B and C)5  RACE
was performed in unstimulated and TNFα-stimulated (10ng/ml for 18h) HUVECs (B) and EA.hy926 cells (C). Nested PCR was performed on 5 RACE cDNA using the outer and inner primer pairs
shownin(A)andproductsofbothreactionswereanalysedona1%agarosegel.ArrowsindicatetheclonedandsequencedRACEproducts.InunstimulatedHUVECs,the5 -UTRofp110δ transcripts
containsa partial exon −1 spliced on to exon 1 withouta −2 exon and in TNFα-stimulated HUVECs,exon −2cspliced on to the full-length exon−1.In both unstimulated and TNFα-stimulated
EA.hy926cells,the5 -UTRofp110δ transcriptsisformedofexon −2esplicedontofull-lengthexon −1orexon −2dsplicedbetweenexons −2eand −1.No5 RACEproductswithexon−2d
as their ﬁrst 5  exon were found although a band with an estimated molecular mass corresponding to such a 5 RACE product is visible on the agarose gel in TNFα-stimulated EA.hy926 cells. The
additional visible bands are degradation products containing partial sequences of exons −2c or −1. (D) Schematic representation of human PIK3CD 5  untranslated exons and their splicing
pattern as identiﬁed by 5 RACE or by PCR ampliﬁcation. M, molecular mass marker.
modiﬁcations at promoter regions 1–3 separately in leucocytes
and non-leucocytes (Figure 4 and Supplementary Figure S3).
A broad enrichment of the H3K4Me3 modiﬁcation associated
with active promoters was found in all three PIK3CD promoter
regions in leucocytes (Figure 4). In contrast, in non-leucocytes,
a strong H3K4Me3 signal was observed only in promoter region
3, with a much weaker H3K4Me3 signal seen in regions 1 and
2 (Figure 4). The pattern of H3K4Me3 enrichment suggests that
all three human PIK3CD promoters are poised for activation in
leucocytes, whereas in non-leucocytes, the promoter region 3 is
likely to act as the preferred start site of PIK3CD transcription.
The enhancer-associated histone modiﬁcations H3K4Me1 and
H3K27Ac showed a similar pattern being highly enriched at all
three promoter regions in leucocytes, but only at region 3 in non-
leucocytes (Supplementary Figure S3).
We extended our analysis to the mouse Pik3cd locus, using
ENCODE data in the UCSC genome browser. As expected,
an enrichment of the H3K4Me3 modiﬁcation was found at
the genomic locations of the known mouse −2 exons in
different mouse tissues and cell types (Supplementary Figure
S4 at http://www.BiochemJ.org/bj/443/bj4430857add.htm). In
addition,similartothehumanPIK3CDlocus,astrongH3K4Me3
signal was also observed upstream of exon −1 in the genomic
region that corresponds to that of the human promoter region 3 in
Figure 4 (Supplementary Figure S4).
Taken together, these results suggest that both the human and
mouse PIK3CD/Pik3cd genes have an alternative, previously
unidentiﬁed, promoter in the genomic region upstream of
exon −1.
TNFα-stimulated expression of distinct PIK3CD transcripts
Given that our bioinformatic analysis strongly suggested that a
functional promoter was associated with the TSSs of exons −2c,
−2d and −2e, we analysed PIK3CD transcript expression by
qPCR with primer/probe sets speciﬁc for the distinct untranslated
exon–exon boundaries (Figure 5A), under basal conditions and
after TNFα stimulation.
In ECs, basal levels of PIK3CD transcripts with exons −2c,
−2d and −2e were low but increased upon TNFα stimulation
(Figures 5B and 5C), in line with our 5
 RACE results. Exon
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Figure 3 Human and mouse PIK3CD/Pik3cd transcripts identiﬁed to date
(A) Human PIK3CD transcripts identiﬁed by 5 RACE in ECs or different human cell types [8] (upper panel) or found in the Ensembl database (lower panel). The PIK3CD transcripts in the Ensembl
database are labelled as follows: A, PIK3CD-202; B, PIK3CD -001; C, PIK3CD-002; D, PIK3CD-201; E, PIK3CD-003; F, PIK3CD-005; G, PIK3CD-006; H, PIK3CD-203; and I, PIK3CD-004).
Transcripts C, D and E lack the canonical exon −1 and instead contain an alternative exon −1 (indicated with an arrow). Evidence for a PIK3CD transcript with an additional upstream exon that is
spliced between exons −2a and −1 and that is located 23kb upstream of exon −2e in the genome was found in an EST isolated from pre-B-cell acute lymphoblastic leukaemia cells (GenBank®
accession number BE246970; not shown). (B) Mouse Pik3cd transcripts identiﬁed by 5 RACE [8] (upper panel) or found in the Ensembl database (lower panel). The Pik3cd transcripts in the
Ensembl database are labelled as follows: A, Pik3cd-001; B, Pik3cd-003; C, Pik3cd-012; D, Pik3cd-201; E, Pik3cd-007; F, Pik3cd-002; G, Pik3cd-008;H, Pik3cd-005; I, Pik3cd-004; J, Pik3cd-009;
K, Pik3cd-010; L, Pik3cd-011; and M, Pik3cd-006. The ﬁrst 5  exon in transcripts E and G is homologous with human exon −2c (indicated with an asterisk). Exons are shown as boxes and introns
are shown as connecting lines.
−2a transcripts were not detected in these cells (Figures 5B and
5C). In synovial ﬁbroblasts, TNFα treatment also stimulated the
expression of exon −2c, −2d and −2e transcripts, as well as
that of exon −2a transcripts (Figure 5D).
In leucocytes (Jurkat and THP-1 cells), exon −2a transcripts
made up the majority of the PIK3CD transcripts (Figures 5E and
5F), in accordance with a previous report [8]. In these cells, exon
−2c-, −2d- or −2e-containing transcripts were only a minor
or undetectable fraction of the total PIK3CD transcript pool,
under both basal and TNFα-stimulated conditions (Figures 5E
and 5F). However, TNFα stimulation induced exon −2a
transcripts in THP-1 cells (Figure 5F), without detectably
altering p110δ protein levels (results not shown), suggesting that
p110δ expression may also be controlled by post-transcriptional
mechanisms in these cells. In summary, PIK3CD transcripts with
5
 -UTRs containing exons −2c, −2d or −2e are detectable at
low levels in unstimulated cells and are further induced by TNFα
stimulation in ECs and synovial ﬁbroblasts, but not in leucocytes.
TNFα stimulation induces the activity of an exon −2e-associated
NF-κB-dependent PIK3CD promoter in ECs
TNFα mediates most of its effects on the transcriptome via the
NF-κB family of TFs. An in silico analysis of TF-binding sites in
the PIK3CD locus identiﬁed four putative NF-κB-binding sites
[κB(1)–(4)] in the genomicregion surroundingexons −2c, −2d
and −2e(Figure6A)withsequencessimilartothatoftheNF-κB
consensus sequence [27] (Figure 6B).
WenextassessedtheTNFα-responsivenessofpromotersofthe
newlyidentiﬁedPIK3CDTSSs.Thegenomicregionssurrounding
exons −2eand −2c(Figure6A)wereinsertedintothepromoter-
less pGL3-Basic luciferase reporter plasmid and their activities
were analysed after transient transfection in unstimulated or
TNFα-stimulated EA.hy926 cells. The basal activity of the exon
−2e promoter was comparable with that of the SV40 (simian
virus40)-drivenpositivecontrolpromoter(Figure6C,whitebars)
and, importantly, was further enhanced upon TNFα stimulation
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Figure 4 Three human PIK3CD promoter regions revealed by bioinformatic analysis of functional regulatory elements
The human PIK3CD locus (chromosome 1, bp 9605000–9715721) in the UCSC genome browser is shown. The RefSeq PIK3CD transcript (on top) contains the untranslated exons −2a and −1
and all of the protein coding exons. The approximate genomic locations of exons −2b, −2c, −2d and −2e are indicated with arrows on top of the RefSeq transcript. Sequence conservation
showsaMultizsequencealignmentfortheindicatedspecies.ForDNaseclustersandTFChIPdata,agreyboxindicatessignalstrengthsothatthedarknessoftheboxisproportionaltothemaximum
signal strength observed. ChIP-seq data for H3K4Me3 are shown separately for non-leucocytes and leucocytes, with data from individual cell types shown in different colours (lower panel). The
promoter regions 1–3 identiﬁed are shown as boxed regions.
(Figure 6C, black bars). In contrast, the basal activity of the
exon −2cpromoterwasmuchweakerandunresponsivetoTNFα
stimulation in these cells (Figure 6C).
ToexaminewhetherthepredictedNF-κBsiteupstreamofexon
−2e was involved in the TNFα-induced promoter activity, the
key residues in the κB(1) site required for NF-κB binding were
mutated(Figure6B,bottomrow).Themutantexon −2epromoter
(−2e-mut) was no longer able to induce luciferase expression
upon TNFα stimulation in EA.hy926 cells (Figure 6D) demon-
strating that the predicted κB(1) site is functional and required
for the TNFα-responsiveness of the exon −2e promoter region.
To further evaluate the role of NF-κBi nt h eT N F α-
induced expression of endogenous p110δ, we used IKK
inhibitor VII to block NF-κB activation and analysed the
expression of PIK3CD mRNA upon TNFα stimulation in
EA.hy926 cells. IKK inhibitor VII inhibited the TNFα-induced
expression of PIK3CD mRNA in a dose-dependent manner
(Figure 6E) at similar concentrations to those that also
inhibited the expression of IL-8 (Supplementary Figure S5A
at http://www.BiochemJ.org/bj/443/bj4430857add.htm) and the
degradation of IκB-α (Supplementary Figure S5B). These results
suggestthatNF-κBisinvolvedintheregulationofTNFα-induced
p110δ expression also in the context of the endogenous p110δ
promoter in EA.hy926 cells.
These data demonstrate that the promoter associated with
human PIK3CD exon −2e is functional and further inducible
in ECs upon stimulation with TNFα. An intact NF-κB-binding
site upstream of exon −2e is required for the TNFα-induced
exon −2e promoter activity. In contrast, the exon −2c promoter
region has weaker basal activity, which cannot be further
enhanced by TNFα stimulation.
Expression of PIK3CD transcripts in human cancer cell lines
Most non-leucocytic cell types express low levels of p110δ under
basal conditions. We chose four non-leucocytic human cancer
cell lines that express intermediate (U-87 MG glioblastoma) or
low (the breast cancer cell lines MCF-7 and MDA-MB-468 and
the SK-OV-3 ovarian carcinoma) levels of p110δ (Figure 7A),
to assess which PIK3CD promoters were used to express p110δ
under unstimulated conditions in these cells.
As expected, exon −2c, −2d and −2e transcripts were
expressed in all non-leucocytic cells with exon −2a transcripts
also found in the breast cancer cell lines MCF-7 and MDA-MB-
468 (Figure 7B). Exon −2b transcripts were only detectable
in THP-1 cells (results not shown). Interestingly, no exon−2a
transcripts were detected in the U-87 MG cell line (Figure 7B)
that expresses p110δ at levels comparable with that in leucocytes
(Figure 7A), suggesting that transcription starting from the
promoter(s) of exons −2c, −2d and −2e can lead to high
cellular p110δ expression.
In conclusion, the novel PIK3CD promoter region identiﬁed in
thepresentstudynotonlyisinduciblebyTNFα inhumanECsand
synovial ﬁbroblasts, but also can allow transcriptional initiation
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Figure5 qPCRanalysisofhumanPIK3CD transcriptexpressionuponTNFα
stimulation
(A) Schematic representation of the distinct human p110δ 5 -UTR structures. The binding sites
of the primer/probe sets used to amplify each transcript are depicted with black bars. (B–F)
Quantitative analysis of PIK3CD transcript expression measured by qPCR in EA.hy926 cells
(B), HUVECs (C), synovial ﬁbroblasts (D), Jurkat cells (E) and THP-1 cells (F) before and
after 8 h of stimulation with 10ng/ml TNFα. Transcript expression was normalized to β-actin
and expressed as the percentage of p110δ-coding transcripts in unstimulated cells. Results are
means+ −S.E.M. for three independent experiments for HUVECs, EA.hy926 cells, Jurkat cells
and THP-1 cells and the mean for one experiment for synovial ﬁbroblasts; experiments were
conducted in trplicate. n.d., not detected.
in non-leucocytic cancer cell lines that express high levels of
p110δ.
DISCUSSION
The functional role of the p110δ PI3K isoform has been widely
studied in cells of the haematopoietic lineage in which p110δ
expression is highly enriched. However, some non-leucocytes
also express p110δ at moderate levels. Our results show that
pro-inﬂammatory cytokines induce the expression of p110δ in
human ECs and synovial ﬁbroblasts, both important stromal cell
types not often associated with p110δ expression or activity. In
addition, we have identiﬁed a novel promoter region for human
PIK3CD that gives rise to transcripts with previously unidentiﬁed
5
 -UTRs. Figure 8 summarizes how this new promoter region
compares with the other p110δ transcriptional elements known to
date.
We previously showed that the exon −2a promoter
allows high basal expression of p110δ in mouse leucocytes
[8]. Our results in human cells on exon −2a transcript
expression, reporter gene assay (Supplementary Figure S6
at http://www.BiochemJ.org/bj/443/bj4430857add.htm) and ana-
lysis of promoter-associated histone modiﬁcations demonstrate
that the promoter of exon −2a (Figure 8, promoter 2) is used to
generatehighbasalexpressionofp110δ alsoinhumanleucocytes.
In addition, expression of human exon −2b transcripts was
highly restricted to leucocytes and the exon −2b promoter
region (Figure 8, promoter 1) showed similar leucocyte-speciﬁc
enrichment of H3K4Me3 as seen in the exon −2a promoter,
suggesting that transcription from the exon −2b TSS also
contributes to high p110δ expression in leucocytes. It is likely
that a combination of regulatory mechanisms together allow
enrichment of p110δ in leucocytes while keeping its expression
low in other cell types. First, there is evidence to suggest
that the exon −2a promoter region might be subject to active
silencing, in a lineage-dependent manner. Indeed, a recent study
demonstrated an inverse correlation between methylation of the
genomic region upstream of PIK3CD exon −2a and p110δ
expressioninhaematopoieticcells[28],suggestingthatleucocyte-
dependent hypomethylation contributes to the enrichment of
p110δ in these cells while keeping p110δ expression low during
early development and in non-haematological cells [28]. It is
not known whether the exon −2b promoter is also regulated
by cell/lineage-dependent methylation. Secondly, the expression
of leucocyte-speciﬁc trans-acting factors have been shown to
be involved in driving high p110δ expression from the exon
−2a promoter [8,29]. In addition, the proteinase MT1-MMP
(membrane-type 1 matrix metalloproteinase) was recently found
to act as a TF that increases p110δ expression in macrophages
through association with the genomic region upstream exon
−1 [9]. Thirdly, recent genome-wide studies have highlighted
the importance of enhancers in driving cell-type-speciﬁc gene
expression [30]. The role of enhancers in regulating lineage-
dependentPIK3CDtranscriptionhasnotbeeninvestigatedtodate,
but is likely to be of importance. However, there is evidence to
suggest that the usage of the −2a and −2b promoters might not
be completely restricted to leucocytes, as a modest enrichment
of H3K4Me3 at these promoters was also observed in human
and mouse non-leucocytes (Figure 4 and Supplementary Figure
S4 respectively) and expression of exon −2a transcripts was
detected in synovial ﬁbroblasts and human breast cancer cells.
In addition to the exon −2a and −2b human PIK3CD
promoters, we now report an alternative third PIK3CD promoter
region (associated with exons −2c, −2d and −2e; Figure 8,
promoter 3) that contributes to basal p110δ expression in all
human cell types. Importantly, transcription starting from this
promoter region can give rise to high p110δ expression as was
seen in the glioblastoma cell line U-87 MG that does not express
PIK3CD transcripts from the exon −2a and −2b promoters
that are active in leucocytes (Figure 7). A corresponding mouse
Pik3cd promoter has not been identiﬁed to date, but is likely to
exist as mouse Pik3cd transcripts with 5
  untranslated exons in
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Figure 6 TNFα-induced exon −2e promoter activity in ECs requires an intact NF-κB site
(A) A schematic representation of the genomic region upstream of human PIK3CD exon −1 (not drawn to scale). PIK3CD exons are depicted as boxes and the genomic regions surrounding
exons −2e and −2c that were inserted into pGL3-Basic are depicted as black bars. The arrows indicate the locations of predicted NF-κB sites [labelled κB(1)–(4)]. (B) The consensus NF-κB
DNA-binding sequence (top row, in bold) and the sequences of κB(1)–(4) sites are shown. The bottom row shows the nucleotides that were mutated to disrupt NF-κB binding to the predicted κB(1)
in the exon −2e-mut construct. (C and D) EA.hy926 cells were transfected with the indicated PIK3CD promoter reporters and stimulated for 24h with 10ng/ml TNFα. The promoter activity of
each reporter is expressed relative to the activity of the SV40 promoter in unstimulated cells (set as 100%). Results are means+ −S.E.M. for three independent experiments. (E) EA.hy926 cells were
pre-treated for 1 h with the indicated concentrations of IKK inhibitor VII or DMSO and stimulated with 10ng/ml TNFα for 6 h. Expression of PIK3CD mRNA was analysed by qPCR and normalized to
18S rRNA. Results are the mean+ −S.E.M. fold increases over expression in unstimulated DMSO-treated cells of three independent experiments. *P <0.05, **P <0.01, ***P <0.001 by two-tailed
unpaired Student’s t test.
Figure 7 p110δ expression under basal conditions in human cancer cell lines
(A) p110δ protein expression in human cancer cell lines. Shown is a representative immunoblot of two independent experiments. (B) qPCR analysis of PIK3CD transcript expression in human
cancer cell lines. Binding sites of the primer/probe sets used to amplify each transcript are shown schematically in Figure 5(A). The expression of each transcript was normalized to β-actin and
expressed as the percentage of p110δ-coding transcripts. Results are means+ −S.E.M. for three independent experiments. n.d., not detected.
the corresponding genomic region are present in the Ensembl
database (Figure 3B) and a clear enrichment of H3K4Me3 can
be seen in the equivalent genomic region in different mouse cell
types (Supplementary Figure S4).
As opposed to basal expression, our 5
 RACE results showed
that the PIK3CD promoter region 3 mediated the TNFα-induced
expression of p110δ in human ECs. To our surprise, no TNFα-
responsive inducibility of the promoter region 3 was seen in
humanleucocytes(JurkatandTHP-1cells).Inourreporterassays
performed in ECs, an NF-κB site upstream of exon −2e was
found to be required for TNFα-responsiveness. However, the
TNFα-inducibleexpressionofp110δ islikelytobemorecomplex
in an in vivo cellular context, and not limited to promoter region
3, given that exposure of synovial ﬁbroblasts and THP-1 cells to
TNFα also induced the expression of p110δ transcripts with the
exon −2a (Figures 5D and 5F).
Our attempts to uncover a function for TNFα-induced p110δ in
ECs or synovial ﬁbroblasts were not successful, as p110δ
inhibition did not affect survival, migration or production of
IL-6 or IL-8 in TNFα-stimulated HUVECs, or production of IL-
6, IL-8 or CCL2 [chemokine (C-C motif) ligand 2] in TNFα-
stimulated synovial ﬁbroblasts (results not shown). Others have
shown that endothelial p110δ activity is involved in selectin-
mediated capture of rolling leucocytes [12,31], an important
endothelial process during inﬂammation, and it is possible that
induced p110δ is important in this biology. Interestingly, a recent
study found that TNFα and IL-1β stimulate the expression of
p110δ in synovial ﬁbroblasts and further implicated p110δ as a
key isoform in PDGF (platelet-derived growth factor)-mediated
Akt activation, cell growth and protection from apoptosis [32].
TNFα target genes differ in the timing of their induction
upon TNFα stimulation: some genes are induced within minutes
of exposure to TNFα and others with much slower kinetics
[33]. Our ﬁndings would place p110δ into the latter group of
TNFα target genes. The activity of p110δ in the endothelium
(or synovium) might thus be dispensable in the early phase of
inﬂammation, but become more important in the resolution phase
or in chronic inﬂammatory states. Despite the high expression
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Figure 8 Overview of the three human PIK3CD promoters
An overview of human PIK3CD promoters identiﬁed to date. The top panel shows a schematic representation of the three promoter regions (highlighted with boxes) and their associated exons with
5  untranslated exons depicted as white boxes and the ﬁrst protein-coding exon as a black box (not drawn to scale). The bottom panel summarizes the characteristics of each promoter. Promoters 1
and 2 are highly active in leucocytes, whereas promoter region 3 has low basal activity in all cell types which can be further enhanced by TNFα in some cell types.
of p110α and p110β relative to p110δ in ECs, we noted an
increase in the contribution of p110δ to the basal p85-associated
PI3K activity in HUVECs upon TNFα stimulation (results not
shown). It is possible, however, that activity from the TNFα-
induced p110δ might be required to synergize with other PI3K
isoforms as is the case in HepG2 cells where insulin-stimulated
PKB phosphorylation is dependent on both p110α and p110δ
activity [34]. Alternatively, TNFα-induced p110δ activity could
be functionally important in a subcellularly localized manner
and thus would not require expression levels similar to p110α
or p110β. Indeed, p110δ activity has been demonstrated to be
important for membrane ﬁssion in the trans-Golgi network in
mouse macrophages [35]. Unfortunately, the lack of speciﬁc
and high-afﬁnity antibodies against p110δ, together with the low
expression of p110δ in ECs, prevented our attempts to examine
the subcellular localization of TNFα-induced p110δ. It was also
of interest to note that TNFα stimulation did not increase the
expression of p110γ, the other class I PI3K isoform whose
expressionislowinnon-leucocytes.Infact,p110γ expressionwas
reduceduponexposureof HUVECs toTNFα (results notshown).
Taken together, we have identiﬁed a third functional human
PIK3CD promoter associated with the upstream exons −2c,
−2d and −2e that has basal activity in both leucocytes and
non-leucocytes, but TNFα-inducible activity only in selected
human non-leucocytes. The differential enrichment of promoter-
and enhancer-associated histone modiﬁcations support cell-type-
speciﬁc usage of PIK3CD TSSs in line with the polarized
expression of p110δ in different cell types. The fact that p110δ
is a non-essential PI3K isoform in the organism (as opposed
to p110α and p110β) might explain the observed versatility in
transcriptional and post-transcriptional regulation of this PI3K
isoform.InadditiontothedifferentPIK3CDtranscriptsgenerated
through alternative TSS usage and splicing at the 5
 -end, the
role of alternative splicing in the p110δ protein-coding region
is underexplored. Interestingly, a novel splice variant of human
PIK3CD was recently identiﬁed in human leucocytes [36]. This
splice variant, generated by usage of an alternative splice site
in intron 5, encodes a C-terminally truncated variant of p110δ
(designated p37δ) that is functionally distinct from the full-length
p110δ protein [36]. Flexible use of exon assembly allows cells
to dynamically respond to their environment, including therapy,
as was recently shown for drug-resistant B-Raf [37], highlighting
the importance of a thorough understanding of the transcriptional
regulation of drug targets.
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Isoform-selective induction of human p110δ PI3K expression by TNFα:
identiﬁcation of a new and inducible PIK3CD promoter
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Figure S1 Comparison of p110δ expression levels in TNFα-stimulated ECs
and unstimulated THP-1 cells
p110δ protein expression in unstimulated and TNFα-stimulated (10ng/ml for 18h) HUVECs
and EA.hy926 cells compared with basal expression levels in THP-1 cells. Equal amounts
(60μg)oftotalcelllysatefromeachsamplewereanalysedbyWesternblottingfortheindicated
proteins.
Figure S2 IL-1β stimulates PIK3CD mRNA expression in HUVECs and
synovial ﬁbroblasts
PIK3CD mRNAexpressionwasanalysedbyqPCRinHUVECsthatwerestimulatedwith20ng/ml
IL-1β for12h(A)andsynovialﬁbroblastswith10 ng/mlIL-1β for18 h(B).PIK3CD transcript
expression was normalized to 18S rRNA and shown as fold increase over unstimulated levels.
ResultsaremeansfortwoexperimentsforHUVECsandthemeans+ −S.E.M.forfourindependent
experiments for synovial ﬁbroblasts. *P <0.05 by two-tailed unpaired Student’s t test.
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Figure S3 Three human PIK3CD promoter regions revealed by bioinformatic analysis of functional regulatory elements
The human PIK3CD locus in the UCSC genome browser as described in the legend to Figure 4 of the main text including ChIP-seq data for enhancer-associated H3K4Me1 and H3K27Ac shown
separately for non-leucocytes and leucocytes.
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Figure S4 Bioinformatics analysis of the mouse Pik3cd locus
ChIP-seq data for the enrichment of H3K4Me3in the mouse Pik3cd locus in the UCSC genome browser. The RefSeq Pik3cd mRNA transcript (on top) contains the untranslated exons −2a and
−1 and all the protein-coding exons. The approximate locations of the untranslated exons −2c, −2d and −2e are indicated with arrows. The boxed regions surrounding exons −2a and −1
correspond to the human PIK3CD promoter regions 2 and 3 respectively (Figure 4 of the main text). Data collected from the indicated tissue and cell types are shown as separate tracks.
Figure S5 IKK inhibitor VII prevents TNFα-stimulated NF-κB activation and IL-8 expression in EA.hy926 cells
(A) EA.hy926 cells were pre-treated for 1h with the indicated concentrations of IKK inhibitor VII or DMSO and stimulated with TNFα (10ng/ml) for 6 h. Expression of IL8 mRNA was analysed by
qPCR and normalized to 18S rRNA. Results are expressed as fold increase over unstimulated DMSO-treated cells are shown as means+ −S.E.M. for three independent experiments. *P <0.05 by
two-tailed unpaired Student’s t test. (B) EA.hy926 cells were pre-treated for 1h with the indicated concentrations of IKK inhibitor VII or DMSO and stimulated for 10min with 10ng/ml TNFα. Levels
of the indicated proteins were analysed by Western blot.
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Figure S6 Human PIK3CD exon −2a promoter has higher activity in
leucocytes than non-leucocytes
PromoteractivityofthegenomicDNAcontaininghumanPIK3CD exon −2aanditsimmediate
upstream sequence (−139 to +92 relative to the start sites of exon −2a) was analysed in
a leucocyte (Jurkat) and a non-leucocyte [HEK (human embryonic kidney)-293T] cell line. The
leucocyte-speciﬁc Vav promoter was used as positive control. Promoter activity is expressed
as a percentage of that of the SV40 promoter (set as 100%) in each cell type. Results are
means+ −S.E.M. for three independent experiments. *P <0.05, **P <0.01 by two-tailed
unpaired Student’s t test.
Table S1 Primer details
SequencedetailsofallthePCRprimersandTaqManqPCRassaysusedinthepresentstudy.Theleft-handcolumnindicatestheexperimentinwhichagivenprimerwasused.FAM,6-carboxyﬂuorescein.
Experiment Primer name Primer sequence (5 →3 )
PIK3CD-speciﬁc primers for 5’RACE OP2 (outer primer) TCGCTGCCCTCAAACTTAACGTT
IP2 (inner primer) AATGGTACCAGGAGTCAAACTCGTGGAGGCCTT
Cloning pGL3-exon-2a reporter pGL3-exon-2a for GACTCTCGAGGCCCTGGAGGACCTGTTGTT
pGL3-exon-2a rev GACTAGATCTGAGTGAGCCTCGAGGGAGGG
Cloning pGL3-exon-2e reporter R1-F6 for ATTAACGCGTGGGGAATGGGGGTGGAGGAAC
R1-R2 rev ATTAAGATCTGAAGTCACACACAGACATTCACTCAA
κB site mutation in pGL3-exon-2e reporter R1_M1_for TGGCTGATTTCTCATCTTGGTTCAAGGAGCGCCCTGGGGGGGTCCGGT
R1_M1_rev ACCGGACCCCCCCAGGGCGCTCCTTGAACCAAGATGAGAAATCAGCCA
PIK3CD exon −1/1 TaqMan assay Forward primer ACTCATTGATTCTAAAGCATCTT
Reverse primer GCATCCTGCGTTGTTACTTC
Probe (FAM) ACTATTCCAGAGAGGACAACTGTCATCT
PIK3CD exon −2a/1 TaqMan assay Forward primer CGAGCAGAGCCGCCCA
Reverse primer AAGATGCTTTAGAATCAATGAGT
Probe (FAM) AGCTGCGCCGGGACATAAGGAGT
PIK3CD exon −2c/1 TaqMan assay Forward primer CCCCTGGGCAACTGTCT
Reverse primer CCGCCCTGGCCTGA
Probe (FAM) CTCCTTATCGGGTGTCGCT
PIK3CD exon −2d/1 TaqMan assay Forward primer CGCACCCCGCTTCCT
Reverse primer TGCTTTAGAATCAATGAGTGTCATCCC
Probe (FAM) CCTGACTCCTTATCTTTGC
PIK3CD exon −2e/1 TaqMan assay Forward primer CCCGGGATCTGTGAAAGCA
Reverse primer CGCCCTGGCCTGACT
Probe (FAM) CCTTATCCGCCCGCACCC
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Table S2 Different cell types analysed for p110δ expression upon TNFα stimulation
Listed are all the different human and mouse cell types that were analysed for the expression of p110δ upon stimulation with TNFα.
Cell name Cell type Effect of TNFα on p110δ expression
THP-1 Human acute monocytic leukaemia cell line 2-Fold increase (mRNA), no effect (protein)
Jurkat Human immortalized T-cell line No effect (protein)
RAW264.7 Mouse macrophage-like cell line No effect (protein)
4T1 Mouse mammary tumour cell line No effect (protein)
MDA-MB-468 Human breast cancer cell line No effect (mRNA)
MDA-MB-231 Human breast cancer cell line No effect (protein)
MCF-7 Human breast cancer cell line 2-Fold increase (mRNA, protein)
HeLa Human cervical cancer cell line No effect (protein)
HEK-293T Human embryonic kidney cell line No effect (mRNA, protein)
BMM Mouse primary bone marrow macrophage No effect (mRNA, protein)
pCEC Mouse primary cardiac endothelial cells No effect (protein)
iCEC Mouse immortalized cardiac endothelial cell line No effect (mRNA, protein)
Lung EC Mouse primary lung endothelial cells No effect (mRNA, protein)
bEND5 Mouse brain endothelial cell line No effect (mRNA, protein)
MEF Mouse primary embryonic ﬁbroblasts 2-Fold increase (mRNA), no effect (protein)
NIH-3T3 Mouse ﬁbroblast cell line No effect (mRNA, protein)
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